Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
Autor: | Robert A. Wolff, Ching Wei D. Tzeng, Michael J. Overman, Chirayu Mohindroo, Shubham Pant, Milind Javle, Wenli Dong, Gauri R. Varadhachary, Michael T. Lotze, Matthew H.G. Katz, Merve Hasanov, David R. Fogelman, Seyda Baydogan, Jane E. Rogers, Florencia McAllister, Michael P. Kim, Jonathan D. Mizrahi, Laura R. Prakash |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
Cancer Research Multivariate analysis Time Factors medicine.medical_treatment Antibiotics Gastroenterology Deoxycytidine antibiotics Research Articles RC254-282 Aged 80 and over Neoplasms. Tumors. Oncology. Including cancer and carcinogens Bacterial Infections Middle Aged Chemotherapy regimen Progression-Free Survival Anti-Bacterial Agents Treatment Outcome Oncology Cohort Adenocarcinoma Female Fluorouracil medicine.drug Carcinoma Pancreatic Ductal Research Article Adult medicine.medical_specialty autophagy medicine.drug_class Antineoplastic Agents chemotherapeutic agents Internal medicine medicine microbiota pancreatic adenocarcinoma Humans Radiology Nuclear Medicine and imaging Aged Retrospective Studies Chemotherapy business.industry Cancer Clinical Cancer Research medicine.disease Gemcitabine immunity Gastrointestinal Microbiome Pancreatic Neoplasms Multivariate Analysis business Epidemiologic Methods |
Zdroj: | Cancer Medicine, Vol 10, Iss 15, Pp 5041-5050 (2021) Cancer Medicine |
ISSN: | 2045-7634 |
Popis: | Recent studies defined a potentially important role of the microbiome in modulating pancreatic ductal adenocarcinoma (PDAC) and responses to therapies. We hypothesized that antibiotic usage may predict outcomes in patients with PDAC. We retrospectively analyzed clinical data of patients with resectable or metastatic PDAC seen at MD Anderson Cancer from 2003 to 2017. Demographic, chemotherapy regimen and antibiotic use, duration, type, and reason for indication were recorded. A total of 580 patients with PDAC were studied, 342 resected and 238 metastatic patients, selected retrospectively from our database. Antibiotic use, for longer than 48 hrs, was detected in 209 resected patients (61%) and 195 metastatic ones (62%). On resectable patients, we did not find differences in overall survival (OS) or progression‐free survival (PFS), based on antibiotic intake. However, in the metastatic cohort, antibiotic consumption was associated with a significantly longer OS (13.3 months vs. 9.0 months, HR 0.48, 95% CI 0.34–0.7, p = 0.0001) and PFS (4.4 months vs. 2 months, HR 0.48, 95% CI 0.34–0.68, p = We have analyzed the effect of antibiotics’ intake on two cohorts of patients with pancreatic adenocarcinoma, resectable, and metastatic. We have found that on the metastatic cohort, antibiotics use was significantly associated with better outcomes, particularly, on patients that received gemcitabine based‐chemotherapy as the first line. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |